Compounds and methods for regulating integrins
View Patent ↗A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.
1. A method for treating diabetic nephropathy, the method comprising:
administering to a patient in need thereof an effective amount of a β2 integrin activating agent and
improving the health of the patient's kidneys,
wherein the β2 integrin activating agent is selected from the group consisting of:
wherein X is selected from O and S,
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the β2 integrin activating agent is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
3. The method of claim 1 , wherein the β2 integrin activating agent is:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the β2 integrin activating agent is:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the β2 integrin activating agent is:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the β2 integrin activating agent is:
or a pharmaceutically acceptable salt thereof.